HomeCompareCPHRF vs XYLD

CPHRF vs XYLD: Dividend Comparison 2026

CPHRF yields 15.38% · XYLD yields 11.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPHRF wins by $28.9K in total portfolio value
10 years
CPHRF
CPHRF
● Live price
15.38%
Share price
$13.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.8K
Annual income
$3,973.98
Full CPHRF calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
11.20%
Share price
$38.36
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$3,351.03
Full XYLD calculator →

Portfolio growth — CPHRF vs XYLD

📍 CPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPHRFXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPHRF + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPHRF pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPHRF
Annual income on $10K today (after 15% tax)
$1,307.69/yr
After 10yr DRIP, annual income (after tax)
$3,377.88/yr
XYLD
Annual income on $10K today (after 15% tax)
$952.37/yr
After 10yr DRIP, annual income (after tax)
$2,848.38/yr
At 15% tax rate, CPHRF beats the other by $529.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPHRF + XYLD for your $10,000?

CPHRF: 50%XYLD: 50%
100% XYLD50/50100% CPHRF
Portfolio after 10yr
$40.3K
Annual income
$3,662.50/yr
Blended yield
9.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CPHRF right now

CPHRF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
8.2
Piotroski
8/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPHRF buys
0
XYLD buys
0
No recent congressional trades found for CPHRF or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPHRFXYLD
Forward yield15.38%11.20%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$54.8K$25.9K
Annual income after 10y$3,973.98$3,351.03
Total dividends collected$26.9K$20.2K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CPHRF vs XYLD ($10,000, DRIP)

YearCPHRF PortfolioCPHRF Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$12,238$1,538.46$10,840$1,120.44+$1.4KCPHRF
2$14,855$1,759.66$11,786$1,249.59+$3.1KCPHRF
3$17,891$1,996.12$12,854$1,397.78+$5.0KCPHRF
4$21,390$2,246.80$14,063$1,568.33+$7.3KCPHRF
5$25,398$2,510.50$15,434$1,765.19+$10.0KCPHRF
6$29,961$2,785.88$16,995$1,993.14+$13.0KCPHRF
7$35,130$3,071.47$18,777$2,257.95+$16.4KCPHRF
8$40,955$3,365.74$20,818$2,566.58+$20.1KCPHRF
9$47,489$3,667.11$23,163$2,927.50+$24.3KCPHRF
10$54,787$3,973.98$25,865$3,351.03+$28.9KCPHRF

CPHRF vs XYLD: Complete Analysis 2026

CPHRFStock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Full CPHRF Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this CPHRF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPHRF vs SCHDCPHRF vs JEPICPHRF vs OCPHRF vs KOCPHRF vs MAINCPHRF vs QYLDCPHRF vs JEPQCPHRF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.